INMED PHARMACEUTICALS INC (INM)
CA4576376012 - Common Stock
Taking everything into account, INM scores 2 out of 10 in our fundamental rating. INM was compared to 193 industry peers in the Pharmaceuticals industry. No worries on liquidiy or solvency for INM as it has an excellent financial health rating, but there are worries on the profitability. INM has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year INM has reported negative net income.
In the past year INM has reported a negative cash flow from operations.
In the past 5 years INM always reported negative net income.
INM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
INM has a worse Return On Assets (-65.14%) than 70.16% of its industry peers.
INM has a Return On Equity of -81.19%. This is comparable to the rest of the industry: INM outperforms 45.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.14% | ||
| ROE | -81.19% | ||
| ROIC | N/A |
ROA(3y)-88.9%
ROA(5y)-97.12%
ROE(3y)-117.99%
ROE(5y)-128.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a Gross Margin value of 31.71%, INM perfoms like the industry average, outperforming 57.07% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for INM so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
INM does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INM has less shares outstanding
INM has more shares outstanding than it did 5 years ago.
There is no outstanding debt for INM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
INM has an Altman-Z score of -15.10. This is a bad value and indicates that INM is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of INM (-15.10) is worse than 81.68% of its industry peers.
There is no outstanding debt for INM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -15.1 |
ROIC/WACCN/A
WACC8.21%
2.3 Liquidity
A Current Ratio of 5.07 indicates that INM has no problem at all paying its short term obligations.
INM has a Current ratio of 5.07. This is in the better half of the industry: INM outperforms 66.49% of its industry peers.
A Quick Ratio of 4.22 indicates that INM has no problem at all paying its short term obligations.
INM's Quick ratio of 4.22 is fine compared to the rest of the industry. INM outperforms 63.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.07 | ||
| Quick Ratio | 4.22 |
3. Growth
3.1 Past
INM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2661.35%.
The Revenue has been growing slightly by 5.32% in the past year.
EPS 1Y (TTM)-2661.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7020.3%
Revenue 1Y (TTM)5.32%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%40.52%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
INM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for INM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INMED PHARMACEUTICALS INC
NASDAQ:INM (12/20/2024, 8:18:34 PM)
4.3988
+0.26 (+6.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners155.53%
Inst Owner Change126.33%
Ins Owners55.57%
Ins Owner Change-0.06%
Market Cap3.17M
Analysts45
Price Target20.4 (363.76%)
Short Float %N/A
Short Ratio0.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.64 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.38 | ||
| P/tB | 0.48 | ||
| EV/EBITDA | N/A |
EPS(TTM)-65.44
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-9.24
FCFYN/A
OCF(TTM)-9.23
OCFYN/A
SpS6.89
BVpS11.66
TBVpS9.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -65.14% | ||
| ROE | -81.19% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 31.71% | ||
| FCFM | N/A |
ROA(3y)-88.9%
ROA(5y)-97.12%
ROE(3y)-117.99%
ROE(5y)-128.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.07 | ||
| Quick Ratio | 4.22 | ||
| Altman-Z | -15.1 |
F-Score3
WACC8.21%
ROIC/WACCN/A
Cap/Depr(3y)35.09%
Cap/Depr(5y)28.33%
Cap/Sales(3y)2.58%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2661.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7020.3%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)5.32%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%40.52%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3.4%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y56.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y56.27%
OCF growth 3YN/A
OCF growth 5YN/A